ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection
ARGX-113-2008
Phase 3 small_molecule active
Quick answer
ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection for Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Argenx
- Indication
- Generalized Myasthenia Gravis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active